Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-45035 in Moderate to Severe Active Rheumatoid Arthritis
NCT07100938Phase 2Terminated
- Sponsor
- BeiGene
- Start
- Aug 2025
- Primary completion
- May 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
A Phase 2 trial of BGB-45035 in rheumatoid arthritis (RA), sponsored by BeiGene. Started Aug 2025; status: terminated.
02
Drugs
BGB-45035
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07100938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100938.